1. Home
  2. NAUT vs PRTC Comparison

NAUT vs PRTC Comparison

Compare NAUT & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nautilus Biotechnolgy Inc.

NAUT

Nautilus Biotechnolgy Inc.

N/A

Current Price

$2.30

Market Cap

383.5M

Sector

Industrials

ML Signal

N/A

Logo PureTech Health plc

PRTC

PureTech Health plc

HOLD

Current Price

$17.42

Market Cap

423.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NAUT
PRTC
Founded
2016
2015
Country
United States
United States
Employees
N/A
56
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
383.5M
423.3M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
NAUT
PRTC
Price
$2.30
$17.42
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$4.00
N/A
AVG Volume (30 Days)
408.3K
4.8K
Earning Date
04-28-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
16.07
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$992.86
N/A
P/E Ratio
N/A
$8.09
Revenue Growth
N/A
N/A
52 Week Low
$0.62
$14.50
52 Week High
$4.31
$19.92

Technical Indicators

Market Signals
Indicator
NAUT
PRTC
Relative Strength Index (RSI) 38.26 51.72
Support Level $2.22 $16.67
Resistance Level $2.30 $18.70
Average True Range (ATR) 0.17 0.76
MACD -0.03 -0.04
Stochastic Oscillator 6.57 30.55

Price Performance

Historical Comparison
NAUT
PRTC

About NAUT Nautilus Biotechnolgy Inc.

Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Its products includes: Proteome Analysis System, Reagent Kits, Software and analysis.

About PRTC PureTech Health plc

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

Share on Social Networks: